Press Releases

  • Cyxone brings forward interim report to August 17, 2018

    August 15, 2018 10:00 (CEST)

    Cyxone AB (publ) announced today that the company has decided to bring forward the publication of the interim report for the period January-June 2018.

  • Cyxone concludes IBD pilot study with its cyclotide

    July 10, 2018 10:31 (CEST)

    Cyxone AB (publ) announced today that the company’s second and last phase of the pilot study in inflammatory bowel disease (IBD) with its cyclotide technology has been concluded. The results add to the growing body of evidence around the cyclotide technology, deepening the understanding of this natural plant protein.

  • Cyxone appoints Mangold as market maker

    June 29, 2018 14:25 (CEST)

    Cyxone AB (publ) announced today that the company has appointed Mangold Fondkommission to provide market making services for the company’s share. The purpose of the market maker is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on July 2, 2018.

  • Cyxone completes acquisition of drug candidate Rabeximod

    June 1, 2018 15:31 (CEST)

    Cyxone AB (publ) announced today that the company has decided to complete the acquisition of drug candidate Rabeximod and issue approximately 1.9 million shares to complete the payment to OxyPharma AB. Cyxone entered into an acquisition agreement with OxyPharma in June 2017 for the drug candidate Rabeximod and now chooses to complete the transaction. The deal has strengthened Cyxone's development portfolio with a candidate in clinical phase II program and broadened the company's portfolio in autoimmune diseases.

  • Interim Report 1 January to 31 March 2018

    May 16, 2018 13:57 (CEST)

    Summary of the Interim Report

  • Cyxone receives notice of patent approval for immunosuppressant treatment with cyclotide T20K

    April 23, 2018 14:14 (CEST)

    Cyxone announced today that the European Patent Office (EPO), has issued its formal intention to approve the company’s patent application regarding the company’s use of cyclotides as immunosuppressive drugs. The approval will strengthen the company’s patent portfolio and ensures the protection of the candidate T20K, which demonstrates beneficial pharmacological effect in preclinical studies against autoimmune diseases, such as multiple sclerosis (MS). 

  • Cyxone’s Annual General Meeting moved to June 5, 2018

    April 20, 2018 17:35 (CEST)

    Cyxone announced today that the date of the company's Annual General Meeting (AGM) will be changed to June 5, 2018 due to the intensification of the work related to the financing of the company's drug candidate Rabeximod.

  • Cyxone’s cyclotides recognized as a potential immunomudulating therapeutics for autoimmune diseases

    April 10, 2018 11:43 (CEST)

    Cyxone announced today that the company’s immunomodulating cyclotide drug, T20K, and its development potential have been recognized in the renowned journal International Journal of Peptide research and Therapeutics. The published scientific article describes the distinct properties of the natural plant protein cyclotides and its demonstrated potential as promising therapeutics in immunopharmacological applications, for example as a treatment for autoimmune diseases.

  • Cyxone’s cyclotide shows promising interim results in IBD pilot study

    March 27, 2018 14:24 (CEST)

    Cyxone announced today that the first phase of their cyclotide pilot study into inflammatory bowel disease (IBD) has been concluded as planned. The study was conducted after an inquiry by a pharmaceutical company that had observed Cyxone’s research for its T20K in multiple sclerosis (MS). Interest was shown for the discovery of the cyclotide’s ability to inhibit a key factor for inflammatory diseases, IL2, and it also appears to accumulate in the intestine and spleen, the organs considered to be involved in IBD. Results from the first phase of the study show a positive effect on the lymph nodes, indicating that the cyclotide reduces T-cell activity, which is considered to be a contributing factor to the uncontrolled inflammation that occurs in IBD.

  • Year-end Report 1 January to 31 December 2017

    February 16, 2018 08:50 (CET)